| Renegade Exploration Limited (RNX) ORDINARY FULLY PAID |
Materials |
$4 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2025 12:34PM |
$0.003 |
$0.002 |
fallen by
33.33%
|
|
RNX - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly activities report and Appendix 5B cash flow report for period ending 31 March 2024.
- Focused on advancing key exploration projects and work programs.
- Reported ongoing expenditure on exploration and evaluation activities.
- No significant production revenues or sales recorded during the quarter.
- Active assessment and progression of resource development opportunities.
- Emphasis on prudent management of cash and expenditures.
- Closing cash balance and financial summary provided.
- Commitment to adding value through strategic exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Opyl Limited (OPL) ORDINARY FULLY PAID |
Information Technology |
- |
Quarterly Activities & Cashflow Report
|
30 Jul 2025 12:34PM |
$0.022 |
$0.022 |
fallen by
0%
|
|
OPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers period ending 31 December 2023.
- Opyl Limited operates Opin and TrialKey, AI-driven clinical trial platforms.
- Continued growth in trial recruitment and retention, with product enhancements.
- Revenue increased due to new and recurring customers.
- Implemented cost controls to extend operational runway.
- Strategic investment in AI and technology platforms.
- Reported ongoing and new contracts in the clinical trial sector.
- Appendix 4C cashflow shows receipts, expenditures and cash position.
- Board and management focus on commercial execution and financial prudence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Firebrick Pharma Limited (FRE) ORDINARY FULLY PAID |
Health Care |
$9 |
Notification of cessation of securities - FRE
|
30 Jul 2025 12:33PM |
$0.077 |
$0.032 |
fallen by
58.44%
|
|
| Wesfarmers Limited (WES) ORDINARY FULLY PAID |
Consumer Discretionary |
$102,174 |
Advance notice - 2025 Full-year results
|
30 Jul 2025 12:31PM |
$84.030 |
$90.055 |
risen by
7.17%
|
|
| Duratec Limited (DUR) ORDINARY FULLY PAID |
Industrials |
$694 |
DURATEC FY25 RESULTS WEBINAR DETAILS
|
30 Jul 2025 12:20PM |
$1.465 |
$2.690 |
risen by
83.62%
|
|
| Activeport Group Ltd (ATV) ORDINARY FULLY PAID |
Information Technology |
$24 |
ATV Secures Additional Circuits adding to contract value
|
30 Jul 2025 12:18PM |
$0.012 |
$0.021 |
risen by
75%
|
|
ATV - Price-sensitive ASX Announcement
Full Release
Key Points
- Activeport Group Ltd secured additional circuit contracts under its network-as-a-service model.
- The new contracts increase the company’s contracted annual recurring revenue (ARR) and total contract value.
- Circuits will be delivered to a major customer in the Asia-Pacific region.
- The announcement is aligned with Activeport’s strategy to expand internationally and serve global enterprise clients.
- Management emphasized the role of software-driven solutions in meeting the demands of scalable and flexible connectivity.
- The new contracts reinforce Activeport’s business growth trajectory and validate its technology platform.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lanthanein Resources Ltd (LNR) ORDINARY FULLY PAID |
Materials |
- |
Application for quotation of securities - LNR
|
30 Jul 2025 12:16PM |
$0.001 |
$0.067 |
risen by
6,600%
|
|
| Acumentis Group Limited (ACU) ORDINARY FULLY PAID |
Real Estate |
$17 |
Response to ASX Appendix 3Y Query
|
30 Jul 2025 12:16PM |
$0.074 |
$0.077 |
risen by
4.05%
|
|
| Fisher & Paykel Healthcare Corporation Limited (FPH) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$18,784 |
Becoming a substantial holder
|
30 Jul 2025 12:13PM |
$33.590 |
$31.985 |
fallen by
4.78%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$515 |
Presentation to BTIG Biotech Conference
|
30 Jul 2025 12:06PM |
$13.200 |
$10.210 |
fallen by
22.65%
|
|
| Rent.com.au Limited (RNT) ORDINARY FULLY PAID |
Communication Services |
$77 |
Notification regarding unquoted securities - RNT
|
30 Jul 2025 12:02PM |
$0.025 |
$0.066 |
risen by
164%
|
|
| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$139 |
Cleansing Notice
|
30 Jul 2025 11:58AM |
$0.310 |
$0.320 |
risen by
3.23%
|
|
| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$139 |
Application for quotation of securities - FDV
|
30 Jul 2025 11:57AM |
$0.310 |
$0.320 |
risen by
3.23%
|
|
| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$139 |
Issue of additional shares to subscribers of InfoCasas
|
30 Jul 2025 11:57AM |
$0.310 |
$0.320 |
risen by
3.23%
|
|
| Tasmea Limited (TEA) ORDINARY FULLY PAID |
Industrials |
$2,463 |
Completion of Vertex Acquisition
|
30 Jul 2025 11:55AM |
$3.660 |
$9.420 |
risen by
157.38%
|
|
| Castle Minerals Limited (CDT) ORDINARY FULLY PAID |
Materials |
$14 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2025 11:52AM |
$0.067 |
$0.077 |
risen by
14.93%
|
|
CDT - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers activities for the period ending 31 March 2023.
- Focus on lithium, gold, and graphite projects in Western Australia and Ghana.
- Significant progress at the Kambale Graphite Project, including feasibility study initiation and drilling.
- Advancement of lithium and gold exploration in Western Australia with new targets and drilling programs.
- Appendix 5B details cash flows, exploration expenditure, and end-of-quarter cash balance.
- Company remains focused on expanding its project portfolio and continuing exploration activities.
- No production or development revenues reported for the quarter.
- Castle Minerals maintains a strong interest in both Australian and Ghanaian assets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Environmental Clean Technologies Limited (ECT) ORDINARY FULLY PAID |
Industrials |
$44 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jul 2025 11:44AM |
$0.003 |
$0.105 |
risen by
4,100%
|
|
ECT - Price-sensitive ASX Announcement
Full Release
Key Points
- ECT advanced its Coldry, HydroMOR, and COHgen technologies during the quarter.
- Significant progress made on the Bacchus Marsh Project construction.
- Ongoing engagement with regulatory authorities and key stakeholders.
- Continued development of zero-emission hydrogen and char production strategies.
- Successful capital raising and funding initiatives completed.
- Technical milestones achieved in the development and pilot testing phases.
- Quarterly cash flow, operational expenditures, and related party payments reported.
- Market conditions and future outlook discussed, with a focus on clean energy transition.
- Commitment to environmental sustainability and commercializing innovative technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tasmea Limited (TEA) ORDINARY FULLY PAID |
Industrials |
$2,463 |
Application for quotation of securities - TEA
|
30 Jul 2025 11:43AM |
$3.670 |
$9.420 |
risen by
156.68%
|
|
| Riedel Resources Limited (RIE) ORDINARY FULLY PAID |
Materials |
$6 |
Notification of cessation of securities - RIE
|
30 Jul 2025 11:38AM |
$0.032 |
$0.022 |
fallen by
31.25%
|
|
| Pantoro Gold Limited (PNR) ORDINARY FULLY PAID |
Materials |
$957 |
Notification of cessation of securities - PNR
|
30 Jul 2025 11:37AM |
$3.735 |
$2.450 |
fallen by
34.40%
|
|
| Empire Resources Limited (ERL) ORDINARY FULLY PAID |
Materials |
$15 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2025 11:36AM |
$0.004 |
$0.007 |
risen by
75%
|
|
ERL - Price-sensitive ASX Announcement
Full Release
Key Points
- ERL completed resource definition and expansion drilling at Penny's Gold Project, with assay results pending.
- Ongoing exploration and assessment activities at Yuinmery Project targeting gold and base metals.
- Expenditure focused primarily on project exploration and necessary administration.
- Strong cash balance maintained, with detailed cash flow movements outlined in Appendix 5B.
- No mining production or development activities were conducted during the quarter.
- Report confirms compliance with ASX Listing Rule 5.3.1 and 5.3.2.
- No payments were made to related parties except for director fees and salaries.
- The company remains committed to progressing its gold assets and evaluating further exploration opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bowen Coking Coal Limited (BCB) ORDINARY FULLY PAID |
Materials |
$8 |
Continuation of Suspension from Quotation
|
30 Jul 2025 11:32AM |
$0.075 |
$0.075 |
fallen by
0%
|
|
| BSA Limited (BSA) ORDINARY FULLY PAID |
Industrials |
$26 |
Notification of cessation of securities - BSA
|
30 Jul 2025 11:17AM |
$0.115 |
$0.340 |
risen by
195.65%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$10 |
Proposed issue of securities - CMB
|
30 Jul 2025 11:14AM |
$0.290 |
$0.370 |
risen by
27.59%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$10 |
Cambium Bio Raises A$2.12 million
|
30 Jul 2025 11:14AM |
$0.290 |
$0.370 |
risen by
27.59%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cambium Bio Limited raised A$2.12 million via a placement to sophisticated and professional investors.
- Funds will be used to advance cell-based therapeutics in regenerative medicine and tissue engineering.
- The capital supports further development of lead product candidates.
- Funding will facilitate ongoing clinical and preclinical programs.
- Proceeds will assist with regulatory submissions and expansion of R&D activities.
- The placement was well supported, reflecting investor confidence in Cambium Bio’s strategy and prospects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
